Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24497548 | 0.82 | METAP2 (0.51) | METAP2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL29739505 | 0.81 | HSP90AA1 (0.50) | METAP2CYP11B1CYP11B2MAPTHSP90AA1 | |
| SCHEMBL16321239 | 0.81 | METAP2 (0.50) | METAP2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL16364563 | 0.81 | METAP2 (0.50) | METAP2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL14988502 | 0.81 | HSP90AA1 (0.50) | METAP2CYP11B1CYP11B2MAPTHSP90AA1 | |
| SCHEMBL27432960 | 0.80 | CCR1 (0.46) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL905134 | 0.79 | CYP1A2 (0.51) | METAP2CYP11B1CYP11B2MAPTALDH1A1 | |
| SCHEMBL29685241 | 0.79 | ALDH1A1 (0.53) | METAP2CYP11B1CYP11B2MAPTHSP90AA1 | |
| SCHEMBL13561342 | 0.78 | METAP2 (0.47) | METAP2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL25109898 | 0.78 | METAP2 (0.47) | METAP2CYP11B1CYP11B2MAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-2271622-B1 | Heteroaryl derivatives as CFTR Modulators | VERTEX PHARMA (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9751890-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-20 | — | — | US | disclosed |
| US-9504683-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150265612-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-09-24 | — | — | US | disclosed |
| US-9079916-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-14 | — | — | US | disclosed |
| US-8796312-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130023538-A1 | Heteroaryl Derivatives as CFTR Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-24 | — | — | US | disclosed |
| EP-0428720-A1 | OPTICALLY ACTIVE COMPOUNDS AND LIQUID CRYSTAL PHASE. | MERCK PATENT GMBH (DE) | 1991-05-29 | — | — | EP | disclosed |
| WO-1990013611-A2 | OPTICALLY ACTIVE COMPOUNDS AND LIQUID CRYSTAL PHASE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | CCR1 3364/4885CCR5 1133/4885CCR8 2801/4885 |
| US-20130023538-A1 | Heteroaryl Derivatives as CFTR Modulators | CFTR, ABCB1, ABCD3 | CCR1 3787/4885CCR5 1286/4885CCR8 3220/4885 |
| US-20150265612-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | CCR1 3364/4885CCR5 1133/4885CCR8 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.